The B Freire A, Jallad R, Batista R, Glezer A, Machado M, Ochman G
Endocr Oncol. 2025; 5(1):e240037.
PMID: 39810846
PMC: 11728929.
DOI: 10.1530/EO-24-0037.
Shigihalli A, Kumar A, Sharma M, Balasubramanian A, Madakshira M
Med J Armed Forces India. 2024; 80(Suppl 1):S430-S432.
PMID: 39734841
PMC: 11670709.
DOI: 10.1016/j.mjafi.2024.02.005.
Jentus M, Bakker L, Verstegen M, Pelsma I, van Wezel T, Ruano D
Endocr Relat Cancer. 2024; 32(1.
PMID: 39441837
PMC: 11729050.
DOI: 10.1530/ERC-24-0070.
Berardinelli J, Russo V, Canciello A, Di Giacinto O, Mauro A, Nardinocchi D
J Clin Med. 2024; 13(15).
PMID: 39124679
PMC: 11312959.
DOI: 10.3390/jcm13154409.
Chaudhary S, Das U, Jabbar S, Gangisetty O, Rousseau B, Hanft S
Neuro Oncol. 2024; 27(1):123-139.
PMID: 39093695
PMC: 11726338.
DOI: 10.1093/neuonc/noae148.
Machine Learning Analysis of Post-Operative Tumour Progression in Non-Functioning Pituitary Neuroendocrine Tumours: A Pilot Study.
Hussein Z, Slack R, Baldeweg S, Mazomenos E, Marcus H
Cancers (Basel). 2024; 16(6).
PMID: 38539533
PMC: 10969734.
DOI: 10.3390/cancers16061199.
Metastatic pituitary tumors: an institutional case series.
Yearley A, Chalif E, Gupta S, Chalif J, Bernstock J, Nawabi N
Pituitary. 2023; 26(5):561-572.
PMID: 37523025
DOI: 10.1007/s11102-023-01341-4.
Pituitary carcinoma: reclassification and implications in the NET schema.
Asa S, Ezzat S
Endocr Oncol. 2023; 2(1):R14-R23.
PMID: 37435449
PMC: 10259303.
DOI: 10.1530/EO-22-0041.
Prognostic Factors for Invasiveness and Recurrence of Pituitary Adenomas: A Series of 94 Patients.
Stefanidis P, Kyriakopoulos G, Seretis A, Korfias S, Theocharis S, Angelousi A
Diagnostics (Basel). 2022; 12(10).
PMID: 36292101
PMC: 9600140.
DOI: 10.3390/diagnostics12102413.
Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S, Vieira Neto L, Soares P, Pires de Carvalho D, Takiya C, Miranda-Alves L
Brain Tumor Pathol. 2022; 39(4):183-199.
PMID: 35725837
DOI: 10.1007/s10014-022-00441-6.
A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.
Nazanin Hosseinkhan , Honardoost M, Emami Z, Cheraghi S, Hashemi-Madani N, Khamseh M
Endocrine. 2022; 77(3):500-509.
PMID: 35711030
DOI: 10.1007/s12020-022-03105-9.
The Past, Present, and Future Statuses of Formerly Classified "Atypical Pituitary Adenomas": A Clinicopathological Assessment of 101 Cases in a Cohort of More than 1,000 Pure Endoscopically Treated Patients in Single Center.
Bal E, Kulac I, Ayhan S, Soylemezoglu F, Berker M
J Neurol Surg B Skull Base. 2021; 82(Suppl 3):e94-e100.
PMID: 34306922
PMC: 8289560.
DOI: 10.1055/s-0040-1702219.
Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M, Nakao T, Ogawa W, Fukuoka H
Front Endocrinol (Lausanne). 2021; 12:650791.
PMID: 34220707
PMC: 8242934.
DOI: 10.3389/fendo.2021.650791.
Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.
Asa S, Mete O, Cusimano M, McCutcheon I, Perry A, Yamada S
Mod Pathol. 2021; 34(9):1634-1650.
PMID: 34017065
DOI: 10.1038/s41379-021-00820-y.
rs98422, rs1011731, rs8017304, and rs2588809 Gene Polymorphisms and Associations With Pituitary Adenoma.
Juknyte G, Laurinaityte I, Vilkeviciute A, Gedvilaite G, Glebauskiene B, Kriauciuniene L
In Vivo. 2021; 35(2):815-826.
PMID: 33622874
PMC: 8045120.
DOI: 10.21873/invivo.12322.
Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?.
Asa S, Mete O, Ezzat S
Endocr Pathol. 2021; 32(1):3-16.
PMID: 33433883
DOI: 10.1007/s12022-021-09663-4.
TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.
Halem H, Hochgeschwender U, Rih J, Nelson R, Johnson G, Thiagalingam A
Endocrinology. 2020; 161(8).
PMID: 32591776
PMC: 7375803.
DOI: 10.1210/endocr/bqaa101.
Identification of gene co-expression modules and hub genes associated with the invasiveness of pituitary adenoma.
Zhou Y, Fu X, Zheng Z, Ren Y, Zheng Z, Zhang B
Endocrine. 2020; 68(2):377-389.
PMID: 32342269
DOI: 10.1007/s12020-020-02316-2.
Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues.
Cozzi R, Ambrosio M, Attanasio R, Bozzao A, De Marinis L, De Menis E
Endocr Metab Immune Disord Drug Targets. 2020; 20(8):1144-1155.
PMID: 31995025
PMC: 7579256.
DOI: 10.2174/1871530320666200129113328.
Long Non-Coding RNA Plasmacytoma Variant Translocation 1 (PVT1) Enhances Proliferation, Migration, and Epithelial-Mesenchymal Transition (EMT) of Pituitary Adenoma Cells by Activating β-Catenin, c-Myc, and Cyclin D1 Expression.
Zhang Y, Tan Y, Wang H, Xu M, Xu L
Med Sci Monit. 2019; 25:7652-7659.
PMID: 31604907
PMC: 6802464.
DOI: 10.12659/MSM.917110.